KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Consolidated Net Income (2016 - 2026)

Biomarin Pharmaceutical has reported Consolidated Net Income over the past 18 years, most recently at $105.5 million for Q1 2026.

  • For the quarter ending Q1 2026, Consolidated Net Income fell 43.17% year-over-year to $105.5 million, compared with a TTM value of $268.7 million through Mar 2026, down 48.7%, and an annual FY2025 reading of $348.9 million, down 18.26% over the prior year.
  • Consolidated Net Income came in at $105.5 million for Q1 2026, up from -$46.6 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $240.5 million in Q2 2025 to a low of -$46.6 million in Q4 2025.
  • Median Consolidated Net Income over the past 5 years was $56.0 million (2023), compared with a mean of $70.0 million.
  • The sharpest move saw Consolidated Net Income soared 8282.73% in 2023, then crashed 137.28% in 2025.
  • Over 5 years, Consolidated Net Income stood at -$249000.0 in 2022, then soared by 8282.73% to $20.4 million in 2023, then skyrocketed by 513.22% to $124.9 million in 2024, then crashed by 137.28% to -$46.6 million in 2025, then soared by 326.58% to $105.5 million in 2026.
  • Per Business Quant, the three most recent readings for BMRN's Consolidated Net Income are $105.5 million (Q1 2026), -$46.6 million (Q4 2025), and -$30.7 million (Q3 2025).